Compare TFIN & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TFIN | NTLA |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2014 | 2016 |
| Metric | TFIN | NTLA |
|---|---|---|
| Price | $72.11 | $12.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 23 |
| Target Price | ★ $66.20 | $20.02 |
| AVG Volume (30 Days) | 148.0K | ★ 3.3M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.22 | 27.43 |
| EPS | ★ 0.67 | N/A |
| Revenue | N/A | ★ $67,671,000.00 |
| Revenue This Year | $7.27 | N/A |
| Revenue Next Year | $11.31 | $62.75 |
| P/E Ratio | $107.34 | ★ N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $46.43 | $7.95 |
| 52 Week High | $83.52 | $28.24 |
| Indicator | TFIN | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 37.60 | 53.32 |
| Support Level | $70.81 | $11.55 |
| Resistance Level | $78.08 | $15.52 |
| Average True Range (ATR) | 1.72 | 0.62 |
| MACD | -0.52 | 0.19 |
| Stochastic Oscillator | 4.12 | 61.23 |
Triumph Financial Inc is a financial holding company based in the United States. Along with its subsidiaries, the company operates in four reportable segments: Banking, Factoring, Payments, and Intelligence. The Banking segment, which generates maximum revenue, includes the operations of TBK Bank, offering traditional banking services. The Factoring segment provides working capital solutions to the trucking industry through the purchase of invoices generated by carriers at a discount. The Payments segment provides payment, audit, and other banking services for the over-the-road trucking industry, and the Intelligence segment operates to turn the over-the-road trucking data collected through the services offered into actionable insights for its customers.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.